Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices 66463 

Name of Committee: Cardiovascular and 

Respiratory Sciences Integrated Review 

Group; Clinical Integrative Cardiovascular 

and Hematological Sciences Study Section. 

Date: October 19–20, 2023. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Embassy Suites Alexandria Old 

Town, 1900 Diagonal Road, Alexandria, VA 

22314. 

Contact Person: Margaret Chandler, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 4126, 

MSC 7814, Bethesda, MD 20892, (301) 435– 

1743, margaret.chandler@nih.gov. 

Name of Committee: Bioengineering 

Sciences & Technologies Integrated Review 

Group; Biodata Management and Analysis 

Study Section. 

Date: October 19–20, 2023. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Bethesdan Hotel, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: E. Bryan Crenshaw, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20892, (301) 480–7129, bryan.crenshaw@

nih.gov. 

Name of Committee: Surgical Sciences, 

Biomedical Imaging and Bioengineering 

Integrated Review Group; Clinical 

Translational Imaging Science Study Section. 

Date: October 19–20, 2023. 

Time: 8:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: North Bethesda Marriott Hotel & 

Conference Center, Montgomery County 

Conference Center Facility, 5701 Marinelli 

Road North, Bethesda, MD 20852. 

Contact Person: Eleni Apostolos Liapi, MD, 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Bethesda, MD 

20817, (301) 867–5309, eleni.liapi@nih.gov. 

Name of Committee: Healthcare Delivery 

and Methodologies Integrated Review Group; 

Interdisciplinary Clinical Care in Specialty 

Care Settings Study Section. 

Date: October 19–20, 2023. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: The Bethesdan Hotel, 8120 

Wisconsin Avenue, Bethesda, MD 20814. 

Contact Person: Abu Saleh Mohammad 

Abdullah, Ph.D., Scientific Review Officer, 

Center for Scientific Review, National 

Institutes of Health, 6701 Rockledge Drive, 

Bethesda, MD 20892, (301) 827–4043, 

abuabdullah.abdullah@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.306, Comparative Medicine; 

93.333, Clinical Research, 93.306, 93.333, 

93.337, 93.393–93.396, 93.837–93.844, 

93.846–93.878, 93.892, 93.893, National 

Institutes of Health, HHS) 

Dated: September 21, 2023. 

David W. Freeman, 

Supervisory Program Analyst, Office of 

Federal Advisory Committee Policy. 

[FR Doc. 2023–20980 Filed 9–26–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Development and 

Commercialization of Engineered T 

Cell Therapies for the Treatment of 

Cancer 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the SUPPLEMENTARY INFORMATION

section of this notice to Moonlight Bio, 

Inc. (‘‘Moonlight’’), headquartered in 

Seattle, WA. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before October 12, 2023 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent applications, inquiries, and 

comments relating to the contemplated 

Exclusive Patent License should be 

directed to: Andrew Burke, Ph.D., 

Senior Technology Transfer Manager, 

NCI Technology Transfer Center, 

Telephone: (240)-276–5484; Email: 

andy.burke@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. United States Provisional Patent 

Application No. 63/492,256 filed March 

27, 2023, entitled ‘‘T Cell Receptors 

Targeting Y220C or R175H Mutation in 

P53’’ [HHS Reference No. E–054–2023– 

0–US–01]. 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be worldwide, and the 

field of use may be limited to the 

following: 

‘‘Development, manufacture and 

commercialization of autologous T cell 

therapy products genetically engineered 

to express a P53 R175H-reactive TCR 

claimed in the Licensed Patent Rights 

for the treatment of cancer in humans.’’ 

The E–054–2023 patent family is 

primarily directed to isolated T cell 

receptors (TCRs) reactive to certain 

mutated forms of tumor protein 53 

(TP53 or P53), within the context of 

several human leukocyte antigens. P53 

is the archetypal tumor suppressor gene 

and the most frequently mutated gene in 

cancer. Contemporary estimates suggest 

that >50% of all tumors carry mutations 

in P53. Because of its prevalence in 

cancer and its restricted expression to 

precancerous and cancerous cells, this 

antigen may be targeted on mutant P53- 

expressing tumors with minimal normal 

tissue toxicity. 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Cancer Institute receives written 

evidence and argument that establishes 

that the grant of the license would not 

be consistent with the requirements of 

35 U.S.C. 209 and 37 CFR part 404. 

In response to this notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially and may be made 

publicly available. 

License applications submitted in 

response to this notice will be presumed 

to contain business confidential 

information and any release of 

information from these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: September 21, 2023. 

Richard U. Rodriguez, 

Associate Director, Technology Transfer 

Center, National Cancer Institute. 

[FR Doc. 2023–21050 Filed 9–26–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 


ddrumheller on DSK120RN23PROD with NOTICES1
66464 Federal Register / Vol. 88, No. 186 / Wednesday, September 27, 2023 / Notices 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; R13 

Conference Grant Review. 

Date: November 14–15, 2023. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W542, Rockville, Maryland 20850 (Virtual 

Meeting). 

Contact Person: Biman Chandra Paria, 

Ph.D., Scientific Review Officer, Program 

Coordination and Referral Branch, Division 

of Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W542, Rockville, Maryland 20850, 

240–858–3814, pariab@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; SBIR Phase 

IIB Bridge Awards. 

Date: November 16, 2023. 

Time: 10:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W238, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Jeffrey E. DeClue, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W238, Rockville, Maryland 

20850, 240–276–6371, decluej@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Small 

Business Transition Grant for Early Career 

Scientists. 

Date: November 30, 2023. 

Time: 9:30 a.m. to 6:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute at Shady 

Grove, 9609 Medical Center Drive, Room 

7W238, Rockville, Maryland 20850 

(Telephone Conference Call). 

Contact Person: Jeffrey E. DeClue, Ph.D., 

Scientific Review Officer, Research 

Technology and Contract Review Branch, 

Division of Extramural Activities, National 

Cancer Institute, NIH, 9609 Medical Center 

Drive, Room 7W238, Rockville, Maryland 

20850, 240–276–6371, decluej@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 21, 2023. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2023–20956 Filed 9–26–23; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Notice of 

Closed Meetings 

Pursuant to section 1009 of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Oncology 2— 

Translational Clinical Integrated Review 

Group; Translational Immuno-oncology 

Study Section. 

Date: October 19–20, 2023. 

Time: 8:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, Bethesda, MD 

20814. 

Contact Person: Maria Elena 

Cardenas-Corona, Ph.D.. Scientific 

Review Officer, Center for Scientific 

Review, National Institutes of Health, 

6701 Rockledge Drive, Bethesda, MD 

20817, 301–867–5309, maria.cardenascorona@nih.gov. 

Name of Committee: Infectious 

Diseases and Immunology B Integrated 

Review Group; Transplantation, 

Tolerance, and Tumor Immunology 

Study Section. 

Date: October 19–20, 2023. 

Time: 8:30 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Canopy by Hilton, 940 Rose 

Avenue, North Bethesda, MD 20852. 

Contact Person: Carmen Angeles 

Ufret-Vincenty, Ph.D., Scientific Review 

Officer, Center for Scientific Review, 

National Institutes of Health, 6701 

Rockledge Drive, Bethesda, MD 20892, 

(301) 594–0912, carmen.ufret-vincenty@

nih.gov. 

Name of Committee: Molecular, 

Cellular and Developmental 

Neuroscience Integrated Review Group; 

Molecular and Cellular 

Neuropharmacology Study Section. 

Date: October 19–20, 2023. 

Time: 9:00 a.m. to 7:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Vanessa S Boyce, 

Ph.D., Scientific Review Officer, Center 

for Scientific Review, National Institutes 

of Health, 6701 Rockledge Drive, Rm. 

4185, MSC 7850, Bethesda, MD 20892, 

(301) 402–3726, boycevs@csr.nih.gov. 

Name of Committee: Center for 

Scientific Review Special Emphasis 

Panel; Collaborative Applications: 

Clinical Studies of Mental Illness. 

Date: October 19, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Allison Kurti, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 

1007J, Bethesda, MD 20892, (301) 594– 

1814, kurtian@csr.nih.gov. 

Name of Committee: Population 

Sciences and Epidemiology Integrated 

Review Group; Neurological, Mental 

and Behavioral Health Study Section. 

Date: October 19–20, 2023. 

Time: 9:00 a.m. to 8:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Allison Kurti, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 

Health, 6701 Rockledge Drive, Room 

1007J, Bethesda, MD 20892, (301) 594– 

1814, kurtian@csr.nih.gov. 

Name of Committee: Vascular and 

Hematology Integrated Review Group; 

Hemostasis, Thrombosis, Blood Cells 

and Transfusion Study Section. 

Date: October 19–20, 2023. 

Time: 9:00 a.m. to 9:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Rockledge II, 6701 Rockledge Drive, 

Bethesda, MD 20892 (Virtual Meeting). 

Contact Person: Vivian Tang, Ph.D., 

Scientific Review Officer, Center for 

Scientific Review, National Institutes of 


ddrumheller on DSK120RN23PROD with NOTICES1